Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Genomic Health Inc (GHDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,213,126
  • Shares Outstanding, K 34,780
  • Annual Sales, $ 327,870 K
  • Annual Income, $ -13,920 K
  • 36-Month Beta 0.66
  • Price/Sales 3.40
  • Price/Cash Flow N/A
  • Price/Book 6.86

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.44 +0.03%
on 01/18/18
37.50 -10.80%
on 12/19/17
-3.49 (-9.45%)
since 12/18/17
3-Month
26.54 +26.04%
on 12/13/17
37.50 -10.80%
on 12/19/17
-0.11 (-0.33%)
since 10/18/17
52-Week
26.37 +26.85%
on 01/24/17
37.50 -10.80%
on 12/19/17
+5.46 (+19.51%)
since 01/18/17

Most Recent Stories

More News
Analysis: Positioning to Benefit within Genomic Health, Worthington Industries, Rambus, OMNOVA Solutions, CAI International, and Rudolph Technologies -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genomic Health, Inc. (NASDAQ:GHDX),...

OMN : 10.55 (-1.40%)
GHDX : 33.45 (-4.10%)
RTEC : 27.85 (+0.91%)
RMBS : 14.26 (-1.66%)
CAI : 29.33 (-3.55%)
WOR : 47.67 (-0.75%)
Invitae Chairman Randy Scott Joins Freenome Board of Directors

Freenome, a health technology company employing advanced machine learning to develop a blood test for early cancer detection, announced today that Randy Scott, Ph.D., has joined the company's...

NVTA : 7.03 (+3.84%)
GHDX : 33.45 (-4.10%)
INCY : 91.92 (+1.78%)
Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference

Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 36th Annual J.P. Morgan Healthcare Conference at...

GHDX : 33.45 (-4.10%)
JPM : 113.26 (+0.24%)
Innovation, Partnership Aid Genomic Health, Cost Woe Remains

Genomic Health's (GHDX) recent positive finds from a string of 10 trials on Oncotype DX Breast Recurrence Score test are likely to buoy investors' optimism.

GHDX : 33.45 (-4.10%)
ATHN : 125.53 (-0.52%)
LMNX : 20.64 (-0.82%)
ALGN : 270.70 (-0.57%)
Genomic Health at a 52-Week High: What's Driving the Stock?

Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.

PETS : 50.57 (-0.61%)
GHDX : 33.45 (-4.10%)
LMNX : 20.64 (-0.82%)
ALGN : 270.70 (-0.57%)
Genomic Health (GHDX) Oncotype DX Score Test Data Positive

Genomic Health (GHDX) forges ahead with development of Oncotype DX Breast Recurrence Score test.

GHDX : 33.45 (-4.10%)
ATHN : 125.53 (-0.52%)
MYGN : 37.99 (+3.12%)
ALGN : 270.70 (-0.57%)
Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus

Genomic Health (GHDX) focuses on notable partnerships to promote its Oncotype DX Genomic Prostate Score (GPS) test.

GHDX : 33.45 (-4.10%)
MYGN : 37.99 (+3.12%)
LMNX : 20.64 (-0.82%)
ALGN : 270.70 (-0.57%)
Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score(TM) Test for Potential Drug Development

Genomic Health, Inc. (NASDAQ: GHDX) today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score(TM) (GPS(TM)) test for...

GHDX : 33.45 (-4.10%)
Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging

Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present 10 Oncotype DX® studies at the 40th San Antonio Breast Cancer Symposium (SABCS), which is being held December 5-9, 2017. Presentation...

GHDX : 33.45 (-4.10%)
Genomic Health-Cleveland Diagnostics Deal to Boost Test Suite

Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.

PETS : 50.57 (-0.61%)
GHDX : 33.45 (-4.10%)
MYGN : 37.99 (+3.12%)
LMNX : 20.64 (-0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict...

See More

Key Turning Points

2nd Resistance Point 35.52
1st Resistance Point 34.49
Last Price 33.45
1st Support Level 32.93
2nd Support Level 32.40

See More

52-Week High 37.50
Last Price 33.45
Fibonacci 61.8% 33.25
Fibonacci 50% 31.94
Fibonacci 38.2% 30.62
52-Week Low 26.37

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.